Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In a randomized trial of 1,412 patients with acute ischemic stroke, reteplase was more likely to result in excellent functional outcomes at 90 days compared to alteplase.
Neurology July 3rd 2024
Oncology News Central (ONC)
Many modern oncology trials prioritize drug approval over patient welfare, often using inferior control arms that do not reflect the best available treatment.
Oncology, Medical July 2nd 2024
The study demonstrates that tirzepatide significantly reduces apnea–hypopnea index and body weight in patients with obstructive sleep apnea and obesity, indicating its potential role in improving both sleep and metabolic health.
Endocrinology, Diabetes, Metabolism July 2nd 2024
In a phase 3 trial, the combination of amivantamab and lazertinib resulted in a median progression-free survival of 23.7 months, surpassing the 16.6 months observed with osimertinib in patients with EGFR-mutated advanced NSCLC.
Oncology, Medical July 1st 2024
In a recent study, 95% of ITP patients treated with the novel anti-CD38 monoclonal antibody, CM313, achieved two consecutive platelet counts of at least 50×10^9 per liter within just eight weeks, highlighting the therapy’s efficacy and rapid action.
Hematology July 1st 2024
A phase 2 trial found that tirzepatide, administered once weekly, significantly improved the resolution of MASH and fibrosis stages in patients with moderate to severe liver fibrosis. These results highlight tirzepatide’s potential as a treatment option, emphasizing the need for further research to validate these findings in larger, long-term studies.
Hepatology June 20th 2024